Literature DB >> 17309322

Therapeutic potential of TGF-beta inhibition in chronic renal failure.

Elena Gagliardini1, Ariela Benigni.   

Abstract

Chronic kidney diseases are emerging as a worldwide public health problem. The progression of kidney diseases closely correlates with the accumulation of extracellular matrix leading to glomerulosclerosis and tubulointerstitial injury. Transforming growth factor (TGF)-beta has been identified as a key mediator of kidney matrix accumulation. Overexpression of TGF-beta isoforms and their receptors was observed in a variety of renal diseases in both animals and humans. Given its crucial role in fibrotic kidney disease, TGF-beta has been recently considered as a possible target in the management of chronic renal diseases. This review discusses the role of TGF-beta in renal fibrosis and provides an overview of the strategies that, when interfering with TGF-beta expression and signalling, could be employed as new renoprotective treatments.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17309322     DOI： 10.1517/14712598.7.3.293

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


  14 in total

1.  In rat renal fibroblasts, mycophenolic acid inhibits proliferation and production of the chemokine CCL2, stimulated by tumour necrosis factor-alpha.

Authors:  Hong-Wei Chang; Vin-Cent Wu; Kwan-Dun Wu; Hong-Yu Huang; Bor-Shen Hsieh; Yung-Ming Chen
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.

Authors:  Mirco Belingheri; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-03       Impact factor: 3.902

3.  Amelioration of glomerulosclerosis with all-trans retinoic acid is linked to decreased plasminogen activator inhibitor-1 and α-smooth muscle actin.

Authors:  Xia Liu; Lei Lü; Bei-bei Tao; Ai-ling Zhou; Yi-chun Zhu
Journal:  Acta Pharmacol Sin       Date:  2011-01       Impact factor: 6.150

4.  Rutin ameliorates renal fibrosis and proteinuria in 5/6-nephrectomized rats by anti-oxidation and inhibiting activation of TGFβ1-smad signaling.

Authors:  Yu Han; Jin-Shan Lu; Yong Xu; Lei Zhang; Bao-Fa Hong
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Evidence of a Role for Fibroblast Transient Receptor Potential Canonical 3 Ca2+ Channel in Renal Fibrosis.

Authors:  Youakim Saliba; Ralph Karam; Viviane Smayra; Georges Aftimos; Joel Abramowitz; Lutz Birnbaumer; Nassim Farès
Journal:  J Am Soc Nephrol       Date:  2014-12-05       Impact factor: 10.121

6.  Myostatin directly regulates skeletal muscle fibrosis.

Authors:  Zhao Bo Li; Helen D Kollias; Kathryn R Wagner
Journal:  J Biol Chem       Date:  2008-05-03       Impact factor: 5.157

7.  Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein.

Authors:  Jonghoon Kang; Myung Soog Lee; John A Copland; Bruce A Luxon; David G Gorenstein
Journal:  Bioorg Med Chem Lett       Date:  2008-02-13       Impact factor: 2.823

Review 8.  Heme oxygenase-1 as a target for TGF-β in kidney disease.

Authors:  Abolfazl Zarjou; Anupam Agarwal
Journal:  Semin Nephrol       Date:  2012-05       Impact factor: 5.299

Review 9.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

10.  A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.

Authors:  Howard Trachtman; Fernando C Fervenza; Debbie S Gipson; Peter Heering; David R W Jayne; Harm Peters; Stefano Rota; Giuseppe Remuzzi; L Christian Rump; Lorenz K Sellin; Jeremy P W Heaton; James B Streisand; Marjie L Hard; Steven R Ledbetter; Flavio Vincenti
Journal:  Kidney Int       Date:  2011-03-02       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.